	1
G3: Genes, Genomes, Genetics	G3: Genes, Genomes, Genetics, 1, 14.29% G3: Genes, Genomes, Genetics 1 publication, 14.29%
bioRxiv	bioRxiv, 1, 14.29% bioRxiv 1 publication, 14.29%
Frontiers in Chemistry	Frontiers in Chemistry, 1, 14.29% Frontiers in Chemistry 1 publication, 14.29%
JCI insight	JCI insight, 1, 14.29% JCI insight 1 publication, 14.29%
Russian Chemical Reviews	Russian Chemical Reviews, 1, 14.29% Russian Chemical Reviews 1 publication, 14.29%
	1

Publishers

	1 2
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 2, 28.57% Cold Spring Harbor Laboratory 2 publications, 28.57%
Oxford University Press	Oxford University Press, 1, 14.29% Oxford University Press 1 publication, 14.29%
IntechOpen	IntechOpen, 1, 14.29% IntechOpen 1 publication, 14.29%
Frontiers Media S.A.	Frontiers Media S.A., 1, 14.29% Frontiers Media S.A. 1 publication, 14.29%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 14.29% American Society for Clinical Investigation 1 publication, 14.29%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 14.29% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 14.29%
	1 2

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Mondaca S. et al. Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer // JCO Precision Oncology. 2018. Vol. 2018. No. 2. pp. 1-4.

GOST all authors (up to 50) Copy

Mondaca S., Lacouture M., Hersch J., Yaeger R. Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer // JCO Precision Oncology. 2018. Vol. 2018. No. 2. pp. 1-4.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1200/po.18.00088

UR - https://doi.org/10.1200/po.18.00088

TI - Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer

T2 - JCO Precision Oncology

AU - Mondaca, Sebastián

AU - Lacouture, Mario

AU - Hersch, Jonathan

AU - Yaeger, Rona

PY - 2018

DA - 2018/11/09

PB - American Society of Clinical Oncology (ASCO)

SP - 1-4

IS - 2

VL - 2018

PMID - 30906913

SN - 2473-4284

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2018_Mondaca,

author = {Sebastián Mondaca and Mario Lacouture and Jonathan Hersch and Rona Yaeger},

title = {Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer},

journal = {JCO Precision Oncology},

year = {2018},

volume = {2018},

publisher = {American Society of Clinical Oncology (ASCO)},

month = {nov},

url = {https://doi.org/10.1200/po.18.00088},

number = {2},

pages = {1--4},

doi = {10.1200/po.18.00088}

}

MLA

Cite this

MLA Copy

Mondaca, Sebastián, et al. “Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer.” JCO Precision Oncology, vol. 2018, no. 2, Nov. 2018, pp. 1-4. https://doi.org/10.1200/po.18.00088.

Publisher

American Society of Clinical Oncology (ASCO)

Journal

JCO Precision Oncology

scimago Q1

wos Q1

SJR

2.409

CiteScore

6.7

Impact factor

5.6

ISSN

24734284 (Electronic)